drugset / Trial / NCT05501769
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer.
Timeline
- Start
- 2022-09-08
- Primary completion
- 2024-07-03
- Completion
- 2025-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vepdegestrant | Other / unclassified | — | Oral |
| Background | Everolimus | Small molecule | — | — |